RxDoctor Payments Data

Carl Shapiro, DO

Pain Medicine · Cincinnati, OHNPI 1144296708

Payments from drug & device makers

$4,571in general payments, 2019–2025

Across 203 payments — averaging $22.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$937
  • SPR Therapeutics, Inc$813
  • Collegium Pharmaceutical, Inc.$662
  • Painteq LLC$611
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$349
  • Biodelivery Sciences International, Inc.$165
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$2616%
  • Food & beverage$3,91486%
  • Education$3979%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,571 in reported general payments places this provider in the 60th percentile of 245 pain medicine providers in Ohio.

See all pain medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$78,257
Medicare patients
88
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate118$114,791
BelbucaBuprenorphine Hcl83$54,003
RelistorMethylnaltrexone Bromide16$39,882
Oxycodone Hcl866$23,471
Diclofenac Sodium74$12,386
Hydromorphone ErHydromorphone Hcl12$12,280
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen302$9,913
MovantikNaloxegol Oxalate19$7,557
LinzessLinaclotide13$7,156
Gabapentin353$4,189
Tizanidine Hcl445$3,351
Morphine Sulfate ErMorphine Sulfate115$3,151
Fentanyl31$3,110
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen142$2,843
Pregabalin124$1,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$662$168,794201 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$349$39,88216 claims
Redhill Biopharma Inc.Movantik$17$7,55719 claims
AbbVieLinzess$937$7,15613 claims
Hikma Pharmaceuticals USAMorphine Sulfate$15$68614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 245 pain medicine providers in Ohio.

Other pain medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →